We are carrying out research to identify biomarkers which can be used for stratification of patients who would most likely benefit from specific psychaitric medications or from adjunct treatments which target specific side effects. In a recent study, we found that the levels of prolactin, fatty acid binding protein, ferritin, C-reactive protein, myoglobin, complement factor H and interleukin-16 could predict improvement in positive symptoms of schizophrenia after antipsychotic treatment and that the levels of insulin and matrix metalloproteinase 2 could be used for prediction of improved negative symptoms. In addition, the same study found that low levels of insulin and leptin and increased levels of TGF-beta were potential predictive markers of short-term relapse.
